Vasopressin receptors: Structure/function relationships and signal transduction in target cells;Les récepteurs de la vasopressine: Structure fonctionnelle et transduction signalétique dans les cellules cibles

Journal de la Societe de Biologie

Volumn 199, Issue 4, 2005, Pages 351-359

  Robert, Jessica ^a   Clauser, Éric ^a  

^a INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33744777739     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2005037     Document Type: Article

References (52)

1. Acher R., Manoussos G. & Olivry G., Relation between oxytocin and Van Dyke's protein and between vasopressin and Van Dyke's protein. Biochim. Biophys. Acta, 1955, 16, 155-156.
2. Aguilera G. & Rabadan-Diehl C., Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Pept., 2000, 96, 23-29.
3. Ahner A. & Brodsky J. L., Checkpoints in ER-associated degradation: excuse me, which way to the proteasome? Trends Cell Biol., 2004, 14, 474-478.
4. Ala Y., Morin D., Mouillac B., Sabatier N., Vargas R., Cotte N., Dechaux M., Antignac C., Arthus M. F., Lonergan M., Turner M. S., Balestre M. N., Alonso G., Hibert M., Barberis C., Hendy G. N., Bichet D. G. & Jard S., Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J. Am. Soc. Nephrol., 1998, 9, 1861-1872.
5. Bermak J. C., Li M., Bullock C. & Zhou Q. Y., Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. Nat. Cell. Biol., 2001, 3, 492-498.
6. Birnbaumer M., Seibold A., Gilbert S., Ishido M., Barberis C., Antaramian A., Brabet P. & Rosenthal W., Molecular cloning of the receptor for human antidiuretic hormone. Nature, 1992, 357, 333-335.
7. Birnbaumer M., Vasopressin receptors. Trends Endocrinol. Metab., 2000, 11, 406-410.
8. Brown C. R., Hong-Brown L. Q., Biwersi J., Verkman A. S. & Welch W. J., Chemical chaperones correct the mutant phenotype of the δ F508 cystic fibrosis transmembrane conductance regulator protein. Cell. Stress Chaperones, 1996, 1, 117-125.
9. Butlen D., Guillon G., Rajerison R. M., Jard S., Sawyer W. H. & Manning M., Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. Mol. Pharmacol., 1978, 14, 1006-1017.
10. 2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Circ. Res., 1996, 78, 813-820.
11. de Keyzer Y. Auzan C., Lenne F., Beldjord C., Thibonnier M., Bertagna X. & Clauser E., Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett., 1994, 356, 215-220.
12. Derick S., Cheng L. L., Voirol M. J., Stoev S., Giacomini M., Wo N. C., Szeto H. H., Ben Mimoun M., Andres M., Gaillard R. C., Guillon G. & Manning M., [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology, 2002, 143, 4655-4664.
13. Duvernay M. T., Zhou F. & Wu G., A conserved motif for the transport of G protein-coupled receptors from the endoplasmic reticulum to the cell surface. J. Biol. Chem., 2004, 279, 30741-30750.
14. Ellgaard L., Riek R., Braun D., Herrmann T., Helenius A. & Wuthrich K., Three-dimensional structure topology of the calreticulin P-domain based on NMR assignment. FEBS Lett., 2001, 488, 69-73.
15. Ellgaard L. & Helenius A., Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell. Biol., 2003, 4, 181-191.
16. Grazzini E., Lodboerer A. M., Perez-Martin A., Joubert D. & Guillon G., Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Endocrinology, 1996, 137, 3906-3914.
17. Guillon G. Derick S., Pena A., Cheng L. L., Stoev S., Seyer R., Morgat J. L., Barberis C., Gal C. S., Wagnon J. & Manning M., The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations. J. Neuroendocrinol., 2004, 16, 356-361.
18. Hawtin S. R., Charged residues of the conserved DRY triplet of the vasopressin V1a receptor provide molecular determinants for cell surface delivery and internalization. Mol. Pharmacol., 2005, 68, 1172-1182.
19. Helenius A. & Aebi M., Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem., 2004, 73, 1019-1049.
20. Jard S., Butlen D., Cantau B., Guillon G., Marie J. & Roy C., The mechanisms of action of antidiuretic hormone. Adv. Nephrol. Necker Hosp., 1984, 13, 163-177.
21. Kopito R. R. & Ron D., Conformational disease. Nat. Cell. Biol., 2000, 2, E207-E209.
22. Krause G., Hermosilla R., Oksche A., Rutz C., Rosenthal W. & Schulein R., Molecular and conformational features of a transport-relevant domain in the C-terminal tail of the vasopressin V(2) receptor. Mol. Pharmacol., 2000, 57, 232-242.
23. Lee B., Yang C., Chen T. H., Al Azawi N. & Hsu W. H., Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am. J. Physiol., 1995, 269, E1095-E1100.
24. Molinari M. & Helenius A., Glycoproteins form mixed disulphides with oxidoreductases during folding in living cells. Nature, 1999, 402, 90-93.
25. Morello J. P., Petaja-Repo U. E., Bichet D. G. & Bouvier M., Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci., 2000a, 21, 466-469.
26. Morello J. P., Salahpour A., Laperriere A., Bernier V., Arthus M. F., Lonergan M., Petaja-Repo U. E., Angers S., Morin D., Bichet D. G. & Bouvier M., Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest., 2000b, 105, 887-895.
27. Morello J. P. & Bichet D. G., Nephrogenic diabetes insipidus. Annu. Rev. Physiol., 2001, 63, 607-630.
28. Morello J. P., Salahpour A., Petaja-Repo U. E., Laperriere A., Lonergan M., Arthus M. F., Nabi I. R., Bichet D. G. & Bouvier M., Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. Biochemistry, 2001, 40, 6766-6775.
29. Mouillac B. Chini B., Balestre M. N., Elands J., Trumpp-Kallmeyer S., Hoflack J., Hibert M., Jard S. & Barberis C., The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J. Biol. Chem., 1995, 270, 25771-25777.
30. Nishikawa S., Brodsky J. L. & Nakatsukasa K., Roles of molecular chaperones in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). J. Biochem. (Tokyo), 2005, 137, 551-555.
31. Oksche A., Dehe M., Schulein R., Wiesner B. & Rosenthal W., Folding and cell surface expression of the vasopressin V2 receptor: requirement of the intracellular C-terminus. FEBS Lett., 1998, 424, 57-62.
32. Oliver J. D., Roderick H. L., Llewellyn D. H. & High S., ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Mol. Biol. Cell, 1999, 10, 2573-2582.
33. Orloff J. & Handler J., The role of adenosine 3′,5′- phosphate in the action of antidiuretic hormone. Am. J. Med., 1967, 42, 757-768.
34. Ostrowski N. L., Lolait S. J. Bradley D. J. O'Carroll A. M., Brownstein M. J. & Young W. S., Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology, 1992, 131, 533-535.
35. Robert J., Auzan C., Ventura M. A. & Clauser E., Mechanisms of cell-surface rerouting of an ER-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone. J. Biol. Chem., 2005, 280, 42198-42206.
36. Robert J., Clauser E., Petit P. & Ventura M. A., A novel C-terminal motif is necessary for the export of the vasopressin V1b/V3 receptor to the plasma membrane. J. Biol. Chem., 2005, 280, 2300-2308.
37. Sadeghi H., Robertson G. L., Bichet D. G., Innamorati G. & Birnbaumer M., Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol. Endocrinol., 1997, 11, 1806-1813.
38. Sato S., Ward C. L., Krouse M. E., Wine J. J. & Kopito R. R., Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem., 1996, 271, 635-638.
39. Schrag J. D., Bergeron J. J., Li Y., Borisova S., Hahn M., Thomas D. Y. & Cygler M., The Structure of calnexin, an ER chaperone involved in quality control of protein folding. Mol. Cell, 2001, 8, 633-644.
40. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G., Lacour C., Guillon G., Barberis C., Brossard G., Soubrie P., Nisato D., Pascal M., Pruss R., Scatton B., Maffrand J. P. & Le Fur G., Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxy-phenyl)sulfonyl]-3-(2-methoxy-phenyl) -2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther., 2002a, 300, 1122-1130.
41. Serradeil-Le Gal C., Wagnon J., Valette G., Garcia G., Pascal M., Maffrand J. P. & Le Fur G., Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res., 2002b, 139, 197-210.
42. Terada Y., Tomita K., Nonoguchi H., Yang T. & Marumo F., Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J. Clin. Invest., 1993, 92, 2339-2345.
43. Thibonnier M., Auzan C., Madhun Z., Wilkins P., Berti-Mattera L. & Clauser E., Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem., 1994, 269, 3304-3310.
44. Thibonnier M., Preston J. A., Dulin N., Wilkins P., Berti-Mattera L. N. & Mattera R., The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology, 1997, 138, 4109-4122.
45. Trombetta E. S. & Parodi A. J., Quality control and protein folding in the secretory pathway. Annu. Rev. Cell. Dev. Biol., 2003, 19, 649-676.
46. Tsukaguchi H., Matsubara H., Taketani S., Mori Y., Seido T. & Inada M., Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus. J. Clin. Invest., 1995, 96, 2043-2050.
47. Wange R. L., Smrcka A., Sternweis P. C. & Exton J. H., Photoaffinity labeling of two rat liver plasma membrane proteins with [32P]gamma-azidoanilido GTP in response to vasopressin. Immunologic identification as alpha subunits of the Gq class of G proteins. J. Biol. Chem., 1991, 266, 11409-11412.
48. Ware F. E., Vassilakos A., Peterson P. A., Jackson M. R., Lehrman M. A. & Williams D. B., The molecular chaperone calnexin binds Glc1Man9GlcNAc2 oligosaccharide as an initial step in recognizing unfolded glycoproteins. J. Biol. Chem., 1995, 270, 4697-4704.
49. Wersinger S. R., Ginns E. I., O'Carroll A. M., Lolait S. J. & Young W. S., 3rd, Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry, 2002, 7, 975-984.
50. Won J. G. & Orth D. N., Role of lipoxygenase metabolites of arachidonic acid in the regulation of adrenocorticotropin secretion by perifused rat anterior pituitary cells. Endocrinology, 1994, 135, 1496-1503.
51. Wuller S., Wiesner B., Loffler A., Furkert J., Krause G., Hermosilla R., Schaefer M., Schulein R., Rosenthal W. & Oksche A., Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J. Biol. Chem., 2004, 279, 47254-47263.
52. Yibchok-Anun S., Cheng H., Heine P. A. & Hsu W. H., Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas. Am. J. Physiol., 1999, 277, 56-62.